Replimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Here's Why

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares were down 5.9% during mid-day trading on Friday . The stock traded as low as $8.91 and last traded at $8.82. Approximately 86,686 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 931,113 shares. The stock had previously closed at $9.37.

Wall Street Analyst Weigh In

Several brokerages have recently commented on REPL. HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, Piper Sandler lifted their price target on shares of Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Replimune Group presently has a consensus rating of "Buy" and an average target price of $19.75.

Replimune Group Trading Up 0.6%

The stock has a market cap of $742.35 million, a PE ratio of -3.14 and a beta of 0.68. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm has a fifty day simple moving average of $8.37 and a two-hundred day simple moving average of $11.07.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the company posted ($0.25) EPS. As a group, equities analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In related news, Director Philip Astley-Sparke sold 32,279 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the transaction, the director now directly owns 1,405,071 shares in the company, valued at $11,324,872.26. The trade was a 2.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Sarchi sold 3,749 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the completion of the sale, the insider now owns 128,296 shares of the company's stock, valued at $1,032,782.80. The trade was a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 74,907 shares of company stock valued at $603,655. Company insiders own 8.80% of the company's stock.

Institutional Trading of Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. Sterling Capital Management LLC lifted its position in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the period. US Bancorp DE raised its stake in Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after buying an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after buying an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd lifted its holdings in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of Replimune Group by 897.2% in the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after buying an additional 7,913 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.